Daniel Kazdal
Daniel Kazdal
PostDoc, Center of Molecular Pathology (CMP), Institute of Pathology, University Hospital Heidelberg
Verified email at
Cited by
Cited by
Automated sample preparation with SP 3 for low‐input clinical proteomics
T Müller, M Kalxdorf, R Longuespée, DN Kazdal, A Stenzinger, ...
Molecular systems biology 16 (1), e9111, 2020
Optimizing panel-based tumor mutational burden (TMB) measurement
J Budczies, M Allgäuer, K Litchfield, E Rempel, P Christopoulos, D Kazdal, ...
Annals of Oncology 30 (9), 1496-1506, 2019
Variant classification in precision oncology
J Leichsenring, P Horak, S Kreutzfeldt, C Heining, P Christopoulos, ...
International journal of cancer 145 (11), 2996-3010, 2019
Harmonization and standardization of panel-based tumor mutational burden measurement: real-world results and recommendations of the quality in pathology study
A Stenzinger, V Endris, J Budczies, S Merkelbach-Bruse, D Kazdal, ...
Journal of Thoracic Oncology 15 (7), 1177-1189, 2020
Spatial and temporal heterogeneity of panel-based tumor mutational burden in pulmonary adenocarcinoma: separating biology from technical artifacts
D Kazdal, V Endris, M Allgäuer, M Kriegsmann, J Leichsenring, ...
Journal of Thoracic Oncology 14 (11), 1935-1947, 2019
Patients resistant against PSMA-targeting α-radiation therapy often harbor mutations in DNA damage-repair–associated genes
C Kratochwil, FL Giesel, CP Heussel, D Kazdal, V Endris, C Nientiedt, ...
Journal of Nuclear Medicine 61 (5), 683-688, 2020
Testing NTRK testing: Wet‐lab and in silico comparison of RNA‐based targeted sequencing assays
N Pfarr, M Kirchner, U Lehmann, J Leichsenring, S Merkelbach‐Bruse, ...
Genes, Chromosomes and Cancer 59 (3), 178-188, 2020
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling
A Stenzinger, M Alber, M Allgäuer, P Jurmeister, M Bockmayr, J Budczies, ...
Seminars in cancer biology 84, 129-143, 2022
Insulinoma-associated protein 1 (INSM1) in thoracic tumors is less sensitive but more specific compared with synaptophysin, chromogranin A, and CD56
K Kriegsmann, C Zgorzelski, D Kazdal, M Cremer, T Muley, H Winter, ...
Applied Immunohistochemistry & Molecular Morphology 28 (3), 237-242, 2020
RNA-based detection of gene fusions in formalin-fixed and paraffin-embedded solid cancer samples
M Kirchner, O Neumann, AL Volckmar, F Stögbauer, M Allgäuer, D Kazdal, ...
Cancers 11 (9), 1309, 2019
MALDI imaging‐guided microproteomic analyses of heterogeneous breast tumors—a pilot study
D Alberts, C Pottier, N Smargiasso, D Baiwir, G Mazzucchelli, P Delvenne, ...
PROTEOMICS–Clinical Applications 12 (1), 1700062, 2018
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma
J Budczies, M Kirchner, K Kluck, D Kazdal, J Glade, M Allgäuer, ...
Oncoimmunology 10 (1), 1860586, 2021
Copy number changes of clinically actionable genes in melanoma, non‐small cell lung cancer and colorectal cancer—A survey across 822 routine diagnostic cases
N Pfarr, R Penzel, F Klauschen, D Heim, R Brandt, D Kazdal, ...
Genes, Chromosomes and Cancer 55 (11), 821-833, 2016
Fusion‐positive non‐small cell lung carcinoma: biological principles, clinical practice, and diagnostic implications
D Kazdal, V Hofman, P Christopoulos, M Ilié, A Stenzinger, P Hofman
Genes, Chromosomes and Cancer 61 (5), 244-260, 2022
Therapeutic and prognostic implications of immune-related adverse events in advanced non-small-cell lung cancer
L Daniello, M Elshiaty, F Bozorgmehr, J Kuon, D Kazdal, H Schindler, ...
Frontiers in Oncology 11, 703893, 2021
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA
S Dietz, P Christopoulos, Z Yuan, AK Angeles, L Gu, AL Volckmar, ...
EBioMedicine 62, 2020
Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer
K Kriegsmann, M Cremer, C Zgorzelski, A Harms, T Muley, H Winter, ...
Pathology 51 (3), 240-245, 2019
Deciphering the immunosuppressive tumor microenvironment in ALK-and EGFR-positive lung adenocarcinoma
J Budczies, M Kirchner, K Kluck, D Kazdal, J Glade, M Allgäuer, ...
Cancer Immunology, Immunotherapy 71 (2), 251-265, 2022
NTRK testing: First results of the QuiP‐EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA‐based …
M Kirchner, J Glade, U Lehmann, S Merkelbach‐Bruse, M Hummel, ...
Genes, Chromosomes and Cancer 59 (8), 445-453, 2020
Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing
P Christopoulos, M Kirchner, J Roeper, F Saalfeld, M Janning, ...
Lung Cancer 148, 105-112, 2020
The system can't perform the operation now. Try again later.
Articles 1–20